Alpha Cognition Inc (ACOG)

Alpha Cognition's stock price has experienced significant fluctuations in the past six months. As of May 30, 2025, the stock had fallen by 42.27% over the preceding six months and underperformed the Toronto Stock Exchange 300 Composite Index by -66.9%. As of its last closing price of CA$7.75, shares were trading -52.14% below their 200-day moving average. Key events include a Q4 2024 capital raise of $52.8 million, the commercial launch of ZUNVEYL in March 2025, Q3 2025 financial results reporting a quarterly loss of $0.3 per share but surpassing revenue estimates with $2.84 million, and the release of a new corporate deck in November 2025 providing commercial data and a path to profitability.

There is no specific information available regarding demand seasonality for Alpha Cognition, Inc.'s products and services. Significant seasonality in demand for its pharmaceutical products is not explicitly indicated.

Alpha Cognition, Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and ALS. Their primary product is ZUNVEYL, an oral tablet for Alzheimer's, designed with minimal gastrointestinal side effects. The company's pipeline includes ALPHA-1062, an acetylcholinesterase inhibitor for Alzheimer's, being developed in combination with memantine and as an intranasal formulation for cognitive impairment with mild Traumatic Brain Injury. Additionally, ALPHA-0602, ALPHA-0702 & ALPHA-0802 (GEMs) is a gene therapy program in preclinical development for ALS, which delivers progranulin, a neurotrophic protein.

Alpha Cognition, Inc. is headquartered in Grapevine, Texas, USA, and Vancouver, British Columbia, Canada. The company launched its commercialization efforts for ZUNVEYL in the U.S. market in March 2025. Its partner, CMS, has filed for approval of ZUNVEYL in China, with an anticipated 18-month review process.

Alpha Cognition's brand reputation has been influenced by its progress in commercializing ZUNVEYL and its financial performance. The successful launch of ZUNVEYL in the U.S. market in March 2025 and the subsequent positive Q3 2025 financial results likely contributed positively to its reputation. The release of a new corporate deck in November 2025 also served to strengthen investor confidence. There is no specific information available detailing negative events that have significantly impacted Alpha Cognition's brand reputation in the past year.

Alpha Cognition is primarily owned by retail investors, who hold 70.18% of the company. Institutional shareholders account for 25.95% of ownership, while Alpha Cognition insiders own 3.86%. Major institutional owners include Solas Capital Management LLC, AWM Investment Company Inc, Ikarian Capital LLC, Cable Car Capital LP, Sphera Funds Management Ltd, Boothbay Fund Management LLC and Aristides Capital LLC. The largest individual shareholder is John Prentiss Havens, owning 285,587.00 shares, representing 1.31% of the company.